BioAdaptives Acquisition Target Xycota Biosciences Launches Free PTSD Tactical & Support Hub for Veterans and First Responders Alongside At-Home Psilocybin Research

Résumé détaillé

Zero-login digital companion offers immediate breathing resets and vetted trauma support today, while Xycota prepares preclinical BDNF/TrkB psilocybin research for practical…

Zero-login digital companion offers immediate breathing resets and vetted trauma support today, while Xycota prepares preclinical BDNF/TrkB psilocybin research for practical outpatient care.

LAS VEGAS, NV AND SHERIDAN, WY / ACCESS Newswire / November 11, 2026 / Recognizing Veterans Day week, BioAdaptives, Inc. (OTCID:BDPT) and its pending acquisition target Xycota Biosciences, LLC today highlighted the public launch of Xycota's free PTSD Community & Resource Hub (https://xycota.com/ptsd), a zero-login digital support and grounding resource built for veterans, active-duty service members, first responders, and caregivers.

Guided by decorated 37-year U.S. Marine Corps Reserve and U.S. Army Reserve combat veteran Lt. Col. Elton Johnson Jr. (Ret.), an incoming Xycota board designee, alongside Xycota Co-Founder and Chief Scientific Officer Marvin S. Hausman, M.D. (a former U.S. Public Health Service Surgeon at the National Institutes of Health), the hub provides practical, zero-cost tools that require no registration and collect no cloud personal health data:

The hub is strictly educational and supportive, does not provide medical advice, and is completely separate from clinical-trial recruitment or enrollment.

Why Real-World Access Drives Xycota's Sub-Perceptual Psilocybin Research

The same real-world barrier shapes Xycota's pharmaceutical research: working veterans, first responders, and parents rarely have six to eight hours to spend inside a clinic for a hallucinogenic therapy session. Xycota's lead investigational candidate, XYCO-02, is a low-dose oral psilocybin capsule designed for potential at-home use below the threshold of noticeable psychedelic effects, targeting the BDNF/TrkB synaptic repair pathway.

In a 2026 Neuropsychopharmacology study (Ascone et al.) co-authored by Dr. Hausman, repeated low-dose oral psilocybin restored object-recognition memory in a genetic rat model of Fragile X syndrome; the benefit held when hallucination-linked serotonin receptors were…

"B…

Début de l'article, extrait de Yahoo Finance. Pour lire la suite, ouvrez l'article chez le média.